6515--534-26-3-783-0091/Stryker Molli ONco Pen (VA-26-00065378)

The solicitation seeks the procurement of the MOLLI ONCO PEN (MP2015A) and MOLLI 2 Tablet (MT2001) system for wire-free, non-radioactive localization and removal of non-palpable soft tissue cancerous lesions in surgical settings. The system must demonstrate precise 3D targeting with real-time visual, auditory, and distance feedback, capable of identifying 3.2 mm markers with 100% success and an average localization time of 17.9 seconds, while supporting IV pole mounting and seamless workflow integration. The requirement is strictly limited to U.S.-made products under a total set-aside for certified Service-Disabled Veteran-Owned Small Businesses (SDVOSB), with a Buy American preference applied under FAR 25.106 and corresponding clauses 52.225-1 and 52.225-2. Non-U.S. sourced items are prohibited unless submitted with full disclosure of domestic content percentage and origin countries, and vendors must provide recent purchase histories to the VA for non-domestic items. All proposals must include full compliance with VA-specific clauses, including limitations on subcontracting, electronic payment submissions via VAAR 852.232-72, SAM registration, and whistleblower protections. Pricing must be clearly identified as either open market or derived from existing contracts such as GSA FSS, GWAC, MPV, or ECAT, and must include all FOB Destination shipping charges. Deliveries are required at W.J.B. Dorn VA Medical Center in Columbia, SC, with inspection and acceptance conducted there based on strict adherence to salient performance characteristics. Evaluation is based on trade-offs between technical compliance and price, with no discussions planned and the government reserving the right to select an offer that is not the lowest-priced. Proposals must be submitted as a single PDF to [email hidden] by May 28, 2026, 10:00 EDT, and must include a completed SF 1449 with UEI, size certification, socioeconomic status, and all applicable certifications. The contract type is inferred as Firm-Fixed-Price under simplified acquisition procedures per FAR Part 13.